{"name":"Myriad Therapeutics, Inc.","slug":"myriad-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOZzIyb0FCSGZNT1RzRnh4NG9LRzNWcFJoX0VwUE9OQkI5eE5BcVBlOGpSaUdic3hYd2ZzcWVSSVluamxhYzBXTC1NZGJkMHJhQUJMNDliTXc3QWplNjQyZngwXzNHUzFnZ2JncTRXOUw3Q0xvUVREbHdnVWlfOW5yN2RnaUxfWTBGTWRMdjE2R243allNWW1ISGJKd2M2c01YQWNv?oc=5","date":"2026-04-07","type":"earnings","source":"IndexBox","summary":"Myriad Genetics Q4 2025 Results: Revenue Beat, Raised Guidance - News and Statistics - IndexBox","headline":"Myriad Genetics Q4 2025 Results: Revenue Beat, Raised Guidance - News and Statistics","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPLU1KX0ZzWDJsYnFKeW5aYWoxTjg1OEh6TXRiUkQwRzhoV2xtdFRFRmNyUGJSckhOOHFaQTJBaVROc0lPZjR1bjJmMFdzN0E0cHk0akNfR25nd2FXd1Vqa0R6d1JPYXJXUzhpQ0dyV2h5WWVzSnNGQmp6akRHbkQxT203bUt0aFJtSVRtQXlMeWRETFl6WXRSVEkyUWREajRjM0UzSDFRUkQxUXc?oc=5","date":"2026-04-06","type":"earnings","source":"Yahoo Finance","summary":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance","headline":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaWU4akxwTnZRTzdDa3RTY1A2VVpnTk5jNWFhSU5FY0tiajN0YmNmSEpQdlpfVnc0WXd0dktjR19FVzZrSXBkVGVRdmRoUDYtcGdZS1ZJV2lCNDdTRjBTS3NJVHBCVXNORnBvak9zMGROaVFrS1JHa0JQU3NHRlV5Y1RZOU5VdWQxTzRzMWpCelBzUkdmQmI2OGF2MVh2MEhtM1d3OVEtTVVrZUFxcW1WMlR4Mk1oaUNBOG1fejdDVk15NzBVYzJaS2h2R0JiM0tZV05admdRbGlXOUUxbTEzckZCMDU?oc=5","date":"2026-04-06","type":"earnings","source":"TradingView","summary":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - TradingView","headline":"Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNbkFEVURFeFd5ZTdQR19EalBnT01ja2F6V3ZDUno0U0J3MmotTEkzbXhrRmNUYlpCNzlIaVBBYU0xRVJLWEJ2Q0VlOFFUWFo5alpPdk83WUxPOHppNmNWUGJnb0pvblc2STF5YkQwRGZzQ09YZksybXpib09jU1JIbkh6TGN6YUVyOUFxRF9idEVfUDVTanpaWTRqeFhha3F1NmxuUzVWWGhqU2dYZ2drdkJRNy1pdl9XSTRNRmROX3JxRnpYME56LWRGM0pHTFFjMHlYN0Z0b2hoUFJ1QWRTN2luSE13RFQ1Y2c?oc=5","date":"2026-03-27","type":"pipeline","source":"StockStory","summary":"Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - StockStory","headline":"Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQTzBKdHFuVkxWdlQ0VGdTNWN6NlpKb3RFcGZKVnhhdkNqQUUxekI2NllMa0hnNGt5VWtyaHpCTUp1VGpLT2lYNURTQnI1WDhvdlROU0dQWTY5ZWk4RFVJUjJRRFljdzVBX3BZSHpHRjVnZDZsVTZ3bTZFT0dJOGh0YjRIRk5hQmQxampSR0duSHU5azgtUm1FVVIzU3JvRjB3d0E?oc=5","date":"2026-03-20","type":"deal","source":"BioSpace","summary":"Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals - BioSpace","headline":"Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPTGxoVUFSbVMwQTlfQUxra1VQLXZoT1JPTFFhd3ZkaWp3QlM5THd1VWlkU0wtX3R1UXdYdFZwZldYbWhtc3RXM1JnMm5sTkQwWURmVUJpX3J3NUNMbHdObUVDazdqdUphNW1DeFhoXzdnMnBtQ2ZVamdvQl9mcjFCWnIxalA1UQ?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc - Yahoo Finance","headline":"Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNY0hNWmlkVG9sZWp4OUlQUDJ6blh6VUF0NHY0NnpvOGZ0Tkc4RmRTblZralVHY19id2RBSkM2T1c4bElhS1d3VVplbm9DQkw5RnVReDBiUG5ua0VmNmtIbkdlNjZ3eXg4Ni00RGVHc0dsTkM5R294TFJXaFk1cXlHMTdqcWliQlQyZDc4TXpYZzBrOVFQaF9SdnhtNXJYZl9rSW9GRFhWSEEtbGtoY3IwdG4xTGZRdUlUVndQMmIyM3JVWDJEQ1NTUGdFUXEzOC0zaXlmOVFXQ0JsdGZLMHBRdg?oc=5","date":"2025-11-11","type":"pipeline","source":"TradingView","summary":"Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know - TradingView","headline":"Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1NMUhva2Z3anY2OEZVM1RKd3BXaWdOVUVtSjNKeVlZV3YwR2JweXlOQVRscVU4YzV6ODQ1Si1GYnNVRFR6SUNiS1l3VGNVdkxJWl90ZDFmZmJZLVNoSE1HdGdLNk9UWC1YZm5XZ2pkQTE2cFNCZ2NaRmxQLVo?oc=5","date":"2025-06-25","type":"pipeline","source":"Pharma Voice","summary":"After myriad failures, a new wave of ALS drugs approaches - Pharma Voice","headline":"After myriad failures, a new wave of ALS drugs approaches","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5EY1VkWE1EODd3cFVWVFQ0STA2aEtqNEJRbTVaZW1qdTJjVUlUZjY0ZV9tV1pZZDhjaWVJTktFaDNydS1nbjctLTlzWDNkYkZyQTJ2YmpGMXJ3bC1nTlIteUNab2JZVFo3QmV2bVhRdVI3aGM?oc=5","date":"2024-09-26","type":"pipeline","source":"Taylor & Francis Online","summary":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer - Taylor & Francis Online","headline":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9TcWZTV1hpdU11dDdrNEN2MVpOejNUdU85cjlfbF9ad2hrUk41REhPanV3T0x3b05CR1pGYWFDcmd5SWNvVlJhWVBUNVF2cDd4eWY0ci1VbTVjelc2RnFv?oc=5","date":"2024-03-07","type":"trial","source":"Nature","summary":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | Molecular Psychiatry - Natur","headline":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depre","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcmh0WjU3U2ZiTXlaRk12Q1ZrdXNpRTM3OVBoWWYxUTlZNzhWNXBWYmFvblVjaVRpTXpsakl5dTd6LTlmSzBWZWdwTmtqVnRhbXZQYUtzZHU2UEtORFh0WGllb19QX0s4STRnOFNoYm11VkpMRGNTUzAwak16cWktXzhIMVFMV2kzd0RkbVYwVGVNcDh4d05DLU5sZW5iS1hNRWlNUg?oc=5","date":"2023-11-03","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Longtime BioMarin CEO hands baton off to Genentech chief - Fierce Biotech","headline":"Chutes & Ladders—Longtime BioMarin CEO hands baton off to Genentech chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPLTBlQ3NpQjRpN3FnMm9pNFVYNDA0eEJZLVdPYU0tX2YzVmk2bl9uQzVEdzJXUjR6ajFtTTlob1h6aW9mMEhVQnU0T19YMFBmcjJWVU8xa3BUdDZXSEg4NXpPX0Z3TVVFalJud1p5RlRmSm1laTNtMHI4ZWJkc05GdTY2VG1qd19vaXdUMGFMdDFvOUR6SnFuWHpJb210WWVHMkF0N2pLSGFrVWdsb0ZBNEFpVHRZcUtvQnlr?oc=5","date":"2020-04-30","type":"pipeline","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer - Intellia Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}